联合PI-RADS v2.1与临床指标诊断PSA≤20 ng/mL患者前列腺癌的列线图开发与验证
回顾性纳入2020年1月至2023年12月218例有病理诊断的患者,分训练集153例与验证集65例,用LASSO回归及logistic回归构建联合PI-RADS v2.1、%fPSA、ADC值和血红蛋白的列线图;模型AUC训练集0.922、验证集0.898,敏感度81.2%、特异度89.3%。
要点
- PSA≤20 ng/mL患者中,PI-RADS v2.1、%fPSA、ADC值和血红蛋白为前列腺癌独立预测因素。
- 联合模型AUC训练集0.922、验证集0.898,高于单一PI-RADS v2.1的0.848。
- 联合模型敏感度81.2%、特异度89.3%,单一PI-RADS v2.1为73.2%和86.8%。
核心结论
- 双参数MRI的PI-RADS v2.1评分对PSA≤20 ng/mL患者前列腺癌检测具独立预测价值,联合临床参数可显著提高诊断可靠性。
研究设计与样本
- 回顾性研究,共218例有病理诊断的患者,训练集153例、验证集65例,采用双参数MRI行PI-RADS v2.1评估,以病理诊断为参考标准。
诊断标准与关键数值
- 联合模型AUC训练集0.922、验证集0.898;单一PI-RADS v2.1的AUC为0.848(P<0.05);%fPSA的AUC为0.760(P<0.001);ADC值的AUC为0.825(P<0.001);血红蛋白的AUC为0.622(P=0.006);联合模型敏感度81.2%、特异度89.3%,单一PI-RADS v2.1敏感度73.2%、特异度86.8%。
临床应用与阅片要点
- 作者认为该联合模型为临床提供无创、可视化评估工具,可能减少侵入性活检的需要,并有助于前列腺癌诊断及治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This investigation focused on developing a predictive clinical tool that combines biparametric MRI-derived PI-RADS v2.1 assessments with patient-specific biomarkers. The model was designed to optimize prostate cancer detection reliability in individuals exhibiting prostate-specific antigen concentrations below 20 ng/mL, particularly targeting the diagnostic challenges presented by this intermediate PSA range. By systematically integrating imaging characteristics with laboratory parameters, the research sought to establish a practical decision-making framework for clinicians managing suspected prostate malignancies.
METHODS: A total of 218 patients with confirmed pathological diagnoses between January 2020 and December 2023 underwent a retrospective review. The cohort was divided into two distinct groups: a training cohort comprising 153 cases and a validation cohort containing 65 cases. For nomogram predictor selection, statistical modeling incorporated machine learning approaches including LASSO regression with ten-fold cross-validation, supplemented by both univariate and multivariate logistic regression analyses to identify independent prognostic factors.The nomogram's predictive performance was evaluated by determining the area under the receiver operating characteristic curve (AUC), developing calibration plots, and implementing decision curve analysis (DCA).
RESULTS: The study findings revealed that among patients with prostate-specific antigen (PSA) concentrations ≤ 20 ng/mL, four parameters - PI-RADS v2.1 classification, free PSA ratio (%fPSA), diffusion-weighted imaging-derived ADC values, and serum hemoglobin concentrations - emerged as independent predictive factors for prostate carcinoma detection. The composite predictive model demonstrated superior diagnostic performance compared to individual parameters, achieving an elevated receiver operating characteristic curve area of 0.922. Notably, the PI-RADS v2.1 scoring system alone showed an AUC of 0.848 (P < 0.05) in this patient cohort. The area under the curve (AUC) for free PSA percentage reached 0.760 (P < 0.001), while apparent diffusion coefficient (ADC) values showed superior discriminative ability with an AUC of 0.825 (P < 0.001). Hemoglobin levels exhibited moderate predictive value (AUC = 0.622, P = 0.006). The developed predictive model exhibited outstanding diagnostic accuracy, achieving AUC scores of 0.922 in the training dataset and 0.898 in the validation cohort, complemented by precise calibration metrics. Integrating PI-RADS v2.1 scores with clinical parameters enhanced diagnostic performance, yielding 81.2% sensitivity and 89.3% specificity in lesion characterization.This marked improvement becomes evident when compared to the standalone application of PI-RADS v2.1, which yielded sensitivity and specificity values of 73.2% and 86.8% correspondingly.
CONCLUSION: The PI-RADS v2.1 assessment derived from biparametric MRI demonstrates standalone prognostic value for detecting prostate malignancies in patients with serum PSA concentrations below 20 ng/mL. This imaging-based scoring system, when integrated with additional clinical parameters, significantly enhances the diagnostic reliability of clinical assessments. The methodology provides clinicians with a non-invasive evaluation tool featuring intuitive visualization capabilities, potentially reducing the necessity for invasive biopsy procedures while maintaining diagnostic precision. This integrated methodology demonstrates considerable promise as an effective framework for improving diagnostic accuracy in PCa identification and supporting therapeutic choices in clinical practice.
引用
- Su Z, Cai B, Li L, et al. Development and validation of a nomogram combining PI-RADS v2.1 and clinical indicators for the diagnosis of prostate cancer in patients with PSA ≤ 20 ng/mL. Abdom Radiol (NY). 2025. PMID: 41081880. doi:10.1007/s00261-025-05231-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。